公开(公告)号：US20160152576A9

公开(公告)日：2016-06-02

申请号：US14170272

申请日：2014-01-31

Applicant: Array BioPharma, Inc.

Inventor： Ian S. Mitchell ,  Keith L. Spencer ,  Peter Stengel ,  Yongxin Han ,  Nicolas C. Kallan ,  Mark Munson ,  Guy P.A. Vigers ,  James Blake ,  Anthony Piscopio ,  John Josey ,  Scott Miller ,  Dengming Xiao ,  Rui Xu ,  Chang Rao ,  Bing Wang ,  April L. Bernacki

IPC: C07D239/94 ,  C07D403/12 ,  C07D495/04 ,  C07D491/048 ,  C07D231/56 ,  C07D401/12 ,  C07D409/04 ,  C07D401/04 ,  C07D409/12 ,  C07D487/04

CPC classification number: C07D239/94 ,  B41M3/008 ,  B44F1/10 ,  C07D231/56 ,  C07D237/28 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D409/04 ,  C07D409/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  G09F13/16 ,  Y10T428/24802 ,  Y10T428/24851 ,  Y10T428/25 ,  Y10T428/31507 ,  Y10T428/31551 ,  Y10T428/31786 ,  Y10T428/31855

Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Abstract translation: 本发明提供包括分解对映异构体，非对映异构体，溶剂化物和药学上可接受的盐的化合物，其包含式为：A-L-CR，其中CR为环状核心基团，L为连接基团，A如本文所定义。 还提供了使用本发明化合物作为AKT蛋白激酶抑制剂和治疗过度增殖性疾病如癌症的方法。

公开(公告)号：US20140315887A1

公开(公告)日：2014-10-23

申请号：US14321468

申请日：2014-07-01

Applicant: Array BioPharma Inc. ,  Genentech, Inc.

Inventor： Josef R. Bencsik ,  James F. Blake ,  Nicholas C. Kallan ,  Ian S. Mitchell ,  Keith L. Spencer ,  Dengming Xiao ,  Rui Xu ,  Christine Chabot ,  Jun Liang ,  Brian S. Safina

IPC: C07D409/12 ,  C07D403/12 ,  C07D239/70

CPC classification number: C07D239/70 ,  A61K31/506 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.